GSK said that the osteosarcoma designation is supported by data from the phase 2 ARTEMIS-002 study ... 3 testing of their ifinatamab deruxtecan (I-DXd) ADC in patients with previously treated ...
The fund may also invest in near cash, other transferable securities, other funds (up to 10%) managed by Artemis and third party funds, money market instruments, and derivatives. The fund may use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback